Recent Updates
Recently added Catalysts
ZTS Neutral Sentiment

Zoetis Announces Second Quarter 2026 Results

Thursday, August 6, 2026 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: Zoetis Inc. has announced its financial results for the second quarter of 2026, reporting revenues of $2.5 billion, which is unchanged from the same period in 2025. The company's net income was reported at $691 million, reflecting a 5% decrease year-over-year. Despite these figures, there was a slight growth in earnings per share.
Price reaction · baseline $74.39 (2026-08-05 close) · hit pre-market · clean, no other ZTS news in the window
day 0 close
+3.9%
day 1
-2.3%
day 3
+1.3%

Market Sentiment Analysis

CONCERNS & RISKS

  • Revenue remained flat compared to the previous year.
  • Net income decreased by 5%, indicating potential financial challenges.

Full Press Release Details

PARSIPPANY, N.J.--(BUSINESS WIRE)---- $ZTS #animalhealth--Zoetis Inc. (NYSE:ZTS), the world's leading animal health company, today reported its financial results for the second quarter of 2026. The company reported revenue of $2.5 billion for the second quarter of 2026, flat compared with the second quarter of 2025, decreasing 1% on an organic operational1 basis. Net income for the second quarter of 2026 was $691 million, or $1.65 per diluted share, decreasing 5% and growing 1%, respectively, on a reported basis. Adj

Frequently Asked Questions

What were Zoetis' revenues for Q2 2026?

Zoetis reported revenues of $2.5 billion for the second quarter of 2026.

How did net income change for Zoetis in Q2 2026?

Net income for Q2 2026 was $691 million, a decrease of 5% from the previous year.

What was the earnings per share for Zoetis in Q2 2026?

The earnings per diluted share for Zoetis in Q2 2026 was $1.65.

How does Q2 2026 revenue compare to Q2 2025?

Revenue for Q2 2026 was flat compared to Q2 2025, with a 1% decrease on an organic basis.

ShareAdd on Google
Tags: ZTS Viatris Investor Conferences Healthcare Zoetis animal health financial results Q2 2026
Last updated: Aug 6, 2026

Biotech snapshot

Cash runway
$1676M liquidity · $0M/mo burn
Low dilution risk